February 7, 2019/Neurosciences/Research

Treatment on Mobile Stroke Unit Improves Functional Outcomes in Acute Ischemic Stroke

Improved 90-day mRS scores mark first demonstration of clinical benefit with a mobile unit

19-NEU-109-mobile-stroke-unit-650×450

For the first time, treatment of patients with acute ischemic stroke on a mobile stroke treatment unit has been shown to result in improved functional outcomes relative to treatment with traditional ambulance transport to an emergency department (ED).

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

That’s the finding of a prospective nonrandomized study by Cleveland Clinic Cerebrovascular Center researchers being presented this week at the 2019 International Stroke Conference in Honolulu. [Editor’s note: The study was also presented as a platform presentation at the American Academy of Neurology’s annual meeting on May 10, 2019.]

“We and others have previously shown that mobile stroke unit care can shorten time to evaluation and thrombolytic therapy in patients with ischemic stroke,” says the study’s senior author, Andrew Russman, DO, Medical Director of Cleveland Clinic’s Comprehensive Stroke Center. “Now we have shown that the accelerated management on the mobile stroke unit is associated with a statistically significant increase in the likelihood of having an excellent or good functional outcome 90 days after the stroke compared with management via traditional ambulance transport to the ED.”

The mobile stroke treatment rationale

The study focused on Cleveland Clinic’s mobile stroke treatment unit (MSTU), a telemedicine-enabled ambulance specially equipped with emergency personnel, a CT scanner and point-of-care lab equipment. As detailed previously on Consult QD, the MSTU’s onboard medical team works to enable patients with suspected stroke to be remotely assessed by Cleveland Clinic vascular neurologists and neuroradiologists via two-way video. Based on the evaluation, the vascular neurologist can order initiation of thrombolysis with IV tissue plasminogen activator (tPA) on the MSTU for appropriate patients, while they are en route to a hospital ED.

“This helps narrow the critical time window to treatment [as reported here] and improves patient triage, helping ensure transport to the hospital destination best suited to a patient’s needs based on the severity of their cerebrovascular event,” Dr. Russman explains. “For instance, evaluation on the MSTU can identify patients who need to be taken to a hospital capable of thrombectomy care, possibly avoiding the need for later transfer.”

Study design at a glance

The researchers compared two groups of patients who received tPA for ischemic stroke:

  • Those evaluated on the MSTU and transported to a Cleveland Clinic hospital
  • Those transported directly to a Cleveland Clinic hospital via emergency medical services (EMS)

Patients had to receive tPA for inclusion in the analysis.

The MSTU group was drawn from 143 consecutive patients transported by the MSTU from July 2014 (when the MSTU was first deployed) through December 2017. After exclusion of patients who were transported to non-Cleveland Clinic hospitals (n = 40), who had stroke mimics (n = 9) or who had incomplete assessment (n = 1), 93 patients were included in the analysis.

The control (EMS) group was drawn from 196 consecutive patients transported by EMS for stroke care at a Cleveland Clinic hospital from January 2015 through December 2017. After exclusion of those with stroke mimics (n = 19) or incomplete assessment (n = 8), 169 were included in the analysis. Patients in the EMS group were treated almost exclusively at Cleveland Clinic’s main campus, which is a Joint Commission-certified Comprehensive Stroke Center.

Advertisement

The primary outcome measure was a modified Rankin Scale (mRS) score of 0 or 1 at 90 days, indicating excellent or good physical function. The mRS score was assessed by standardized telephone interview and review of medical records approximately 90 days after stroke. If a phone interview at 90 days could not be obtained, 90-day mRS score was estimated based on medical records since the time of stroke.

Results: Doubling the likelihood of excellent or good outcome

The MSTU and EMS groups were statistically comparable on demographic variables, with three exceptions: Patients in the MSTU group were significantly more likely to be female, to have atrial fibrillation and to undergo endovascular treatment for their stroke. “The latter difference suggests that mobile stroke treatment may allow us to identify the need for endovascular therapy earlier,” Dr. Russman observes.

Time to treatment differed significantly between the groups, as follows:

  • Mean time from symptom onset to tPA administration was shorter in the MSTU group (83 minutes) than in the EMS group (117 minutes) (P < .001).
  • More patients received tPA within 90 minutes from symptom onset in the MSTU group (53.8 percent) than in the EMS group (29.0 percent) (P < .001).

Advertisement

On the primary outcome measure, a 90-day mRS score of 0 or 1 was achieved by 42 percent of patients in the MSTU group versus 33 percent of those in the EMS group. While this difference was not statistically significant on unadjusted analysis, it became significant after binary logistic regression analysis to adjust for confounding variables, with MSTU transport having an odds ratio of 2.06 (95% CI, 1.01-4.19; P = 0.046) for an mRS score of 0 or 1 relative to EMS transport.

“Mobile stroke care doubled patients’ likelihood of having an excellent or good functional outcome,” Dr. Russman notes. “This finding is particularly impressive because virtually all the patients in the EMS group were transported to Cleveland Clinic’s main campus, which is a Comprehensive Stroke Center. This very high level of care in the comparator group makes it all the harder for mobile stroke care to have demonstrated incremental benefit.”

Findings in context

“These findings further confirm the value of mobile stroke treatment by showing for the first time that benefit extends beyond faster evaluation and treatment to include superior functional outcomes,” Dr. Russman continues. He notes that an earlier assessment of patients’ functional outcomes in a German group’s study of their mobile stroke unit failed to show a significant treatment effect.

Dr. Russman speculates that the difference may stem from variations in the German and Cleveland Clinic mobile stroke treatment models. “The German group does some triage on their mobile unit, but they don’t routinely do CT angiograms to identify large vessel occlusions the way that we do on our unit, which allows us to take patients with such occlusions straight to thrombectomy-capable settings,” he says. “This difference in triage and transfer may explain the difference in impact between the German study and ours.”

He adds, however, that definitive confirmation of an outcomes benefit from mobile stroke treatment awaits results of a randomized controlled trial. Such a study, known as BEST-MSU, is now underway.

In addition to its nonrandomized nature, Dr. Russman says his group’s study was also limited by the fact that it excluded MSTU patients who were transferred to non-Cleveland Clinic hospitals.

An additional caveat comes from a subanalysis that found the MSTU treatment effect was no longer significant after exclusion of patients who no longer had imaging evidence of a stroke after treatment with tPA. “These cases theoretically could represent stroke mimics,” he says, “although we believe the tPA aborted the stroke in these cases.” He notes that the odds ratio for a mRS of 0 or 1 was still 2.06 in the MSTU group with these cases excluded but it was no longer quite statistically significant.

“While further study is needed,” Dr. Russman concludes, “these results bolster the case that a mobile stroke unit can maximize not only the timeliness of care but the quality of care in terms of both tPA administration and the triaging of patients for optimal follow-on care.”

The study results will be submitted for journal publication shortly.

Advertisement

Related Articles

illustration of an alzheimer brain and a packet of sildenafil pills
March 11, 2024/Neurosciences/Research
Sildenafil as an Alzheimer’s Candidate Drug: Further Support From Insurance Database and Mechanistic Studies

Real-world claims data and tissue culture studies set the stage for randomized clinical testing

22-NEU-2959102-CQD-Hero-650&#215;450
June 15, 2022/Neurosciences/Research
MINDS Study Will Assess Lifestyle Interventions for Slowing Brain Pathology in Preclinical Stages

New grant-funded investigation illustrates impact and reach of Cleveland Clinic Brain Study

22-NEU-2671014-CQD-650&#215;450-Type
March 9, 2022/Neurosciences/Research
A Closer Look at the Cleveland Clinic Brain Study

How the new longitudinal investigation could become the Framingham Heart Study of brain health

20-NEU-1959738 powered-exoskeleton-for-gait-training_650x450
October 23, 2020/Neurosciences/Research
Study Signals Potential of Powered Exoskeleton for Gait Training in Multiple Sclerosis

Pilot findings show good patient acceptance and safety, early hints of efficacy

20-NEU-1990660-sleep-symptoms-in-health-workers-650&#215;450
October 21, 2020/Neurosciences/Research
Electronic Screening for Sleep Disorders Among Healthcare Workers Is Feasible – and Sorely Needed

Study finds high prevalence of symptoms, willingness to seek treatment

20-NEU-1946228 neurofilaments_650x450
September 9, 2020/Neurosciences/Research
Serum Neurofilament Light as a Progressive MS Biomarker: Guideposts for the Road Ahead

Panel outlines research priorities around a promising alternative to imaging markers

20-NEU-1951118_Impella-temporary-LVAD_650x450_ (1)
September 4, 2020/Neurosciences/Research
Study Finds Clues to Acute Neurologic Events With Short-Term Impella Cardiac Support

Suspected factors include antithrombotic intensity, time on device, presence of thrombocytopenia

20-NEU-1929179 deep-brain-stimulation-for-TBI_650x450
September 3, 2020/Neurosciences/Research
Could DBS of the Cerebellar Dentate Nucleus Enhance Post-TBI Rehabilitation?

Preclinical studies will assess whether method developed for stroke recovery curbs deficits after brain injury

Ad